Background The metabolic basis of Alzheimer disease (AD) is poorly understood, and the
relationships between systemic abnormalities in metabolism and AD pathogenesis are …

Alzheimer's Disease (AD) currently affects more than 5 million Americans, with numbers
expected to grow dramatically as the population ages. The pathophysiological changes in …

The development of Alzheimer's dementia (AD) accompanies both central and peripheral
metabolic disturbance, but the metabolic basis underlying AD and metabolic markers …

Background Metabolic alterations, related to cerebral glucose metabolism, brain insulin
resistance, and age-induced mitochondrial dysfunction, play an important role in Alzheimer's …

Metabolites, the biochemical products of the cellular process, can be used to measure
alterations in biochemical pathways related to the pathogenesis of Alzheimer's disease …

Background Alzheimer's disease (AD) is a complex neurological disorder with contributions
from genetic and environmental factors. High‐resolution metabolomics (HRM) has the …

Background: Metabolites are biological compounds reflecting the functional activity of
organs and tissues. Understanding metabolic changes in Alzheimer's disease (AD) can …

The pathogenic mechanisms of Alzheimer's disease (AD) remain largely unknown and
clinical trials have not demonstrated significant benefit. Biochemical characterization of AD …

Progress toward the development of efficacious therapies for Alzheimer's disease (AD) is
halted by a lack of understanding early underlying pathological mechanisms. Systems …

Alzheimer's disease (AD) is the most common cause of dementia, accounting for an
estimated 60–80% of cases, and is the sixth-leading cause of death in the United States …